الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Cardioplegia is responsible for myocardial protection during open heart surgery and provides static and bloodless field to facilitate surgical procedures.
The perfect cardioplegic solution for myocardial protection during cardiac surgery is still controversial.
It was demonstrated that custodiol HTK solution can be safely used as a cardioplegic solution. It is given as a single dose. In addition, it can provide adequate myocardial protection for up to 3 h. Moreover, custodiol is preferable among cardiac surgeons as it ensures uninterrupted open-heart procedures.
Our prospective randomized clinical trial study was conducted to compare the ejection fraction using Trans-esophageal echocardiography and need for cardiac support of custodiol cardioplegic solution versus traditional crystalloid solution in patients undergoing on-pump coronary artery bypass graft surgery using aid of trans- esophageal echocardiography.
Following the departmental research committee and informed patients consent, patients undergoing on-pump coronary artery bypass graft surgery in Suez Canal University Hospital, were randomly assigned to one of the two groups using a table of random numbers with allocation ratio one to one. The random sequence was concealed in opaque randomed envelopes that was opened in day of surgery.
Including: Patients who were more than 21 and less than 60 years of age, of both sexes, ASA III patients (American Society of Anesthesiologists physical status Grade III) = (patients with moderate systemic disease and some functional limitations) and in patients with low ejection fraction less than 40%, and patients of BMI more than 20 and less than 34.